Phase I Study to Determine the Safety and Tolerability of the Oral Microtubule Destabilizer BAL101553 in Combination With Standard Radiation in Patients With MGMT Promoter Unmethylated Newly Diagnosed Glioblastoma
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 24 May 2018
At a glance
- Drugs Lisavanbulin (Primary)
- Indications Glioblastoma
- Focus Adverse reactions
- 11 May 2018 Planned End Date changed from 15 Jul 2021 to 15 Jul 2022.
- 11 May 2018 Planned primary completion date changed from 15 Jul 2019 to 15 Jul 2020.
- 11 May 2018 Status changed from recruiting to active, no longer recruiting.